Cargando…
Determining breast cancer biomarker status and associated morphological features using deep learning
BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretatio...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037318/ https://www.ncbi.nlm.nih.gov/pubmed/35602213 http://dx.doi.org/10.1038/s43856-021-00013-3 |
_version_ | 1784693709807288320 |
---|---|
author | Gamble, Paul Jaroensri, Ronnachai Wang, Hongwu Tan, Fraser Moran, Melissa Brown, Trissia Flament-Auvigne, Isabelle Rakha, Emad A. Toss, Michael Dabbs, David J. Regitnig, Peter Olson, Niels Wren, James H. Robinson, Carrie Corrado, Greg S. Peng, Lily H. Liu, Yun Mermel, Craig H. Steiner, David F. Chen, Po-Hsuan Cameron |
author_facet | Gamble, Paul Jaroensri, Ronnachai Wang, Hongwu Tan, Fraser Moran, Melissa Brown, Trissia Flament-Auvigne, Isabelle Rakha, Emad A. Toss, Michael Dabbs, David J. Regitnig, Peter Olson, Niels Wren, James H. Robinson, Carrie Corrado, Greg S. Peng, Lily H. Liu, Yun Mermel, Craig H. Steiner, David F. Chen, Po-Hsuan Cameron |
author_sort | Gamble, Paul |
collection | PubMed |
description | BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretation. Additionally, discordances between histology and expected biomarker findings can prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results. METHODS: We developed three independent deep learning systems (DLS) to directly predict ER/PR/HER2 status for both focal tissue regions (patches) and slides using hematoxylin-and-eosin-stained (H&E) images as input. Models were trained and evaluated using pathologist annotated slides from three data sources. Areas under the receiver operator characteristic curve (AUCs) were calculated for test sets at both a patch-level (>135 million patches, 181 slides) and slide-level (n = 3274 slides, 1249 cases, 37 sites). Interpretability analyses were performed using Testing with Concept Activation Vectors (TCAV), saliency analysis, and pathologist review of clustered patches. RESULTS: The patch-level AUCs are 0.939 (95%CI 0.936–0.941), 0.938 (0.936–0.940), and 0.808 (0.802–0.813) for ER/PR/HER2, respectively. At the slide level, AUCs are 0.86 (95%CI 0.84–0.87), 0.75 (0.73–0.77), and 0.60 (0.56–0.64) for ER/PR/HER2, respectively. Interpretability analyses show known biomarker-histomorphology associations including associations of low-grade and lobular histology with ER/PR positivity, and increased inflammatory infiltrates with triple-negative staining. CONCLUSIONS: This study presents rapid breast cancer biomarker estimation from routine H&E slides and builds on prior advances by prioritizing interpretability of computationally learned features in the context of existing pathological knowledge. |
format | Online Article Text |
id | pubmed-9037318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90373182022-05-20 Determining breast cancer biomarker status and associated morphological features using deep learning Gamble, Paul Jaroensri, Ronnachai Wang, Hongwu Tan, Fraser Moran, Melissa Brown, Trissia Flament-Auvigne, Isabelle Rakha, Emad A. Toss, Michael Dabbs, David J. Regitnig, Peter Olson, Niels Wren, James H. Robinson, Carrie Corrado, Greg S. Peng, Lily H. Liu, Yun Mermel, Craig H. Steiner, David F. Chen, Po-Hsuan Cameron Commun Med (Lond) Article BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretation. Additionally, discordances between histology and expected biomarker findings can prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results. METHODS: We developed three independent deep learning systems (DLS) to directly predict ER/PR/HER2 status for both focal tissue regions (patches) and slides using hematoxylin-and-eosin-stained (H&E) images as input. Models were trained and evaluated using pathologist annotated slides from three data sources. Areas under the receiver operator characteristic curve (AUCs) were calculated for test sets at both a patch-level (>135 million patches, 181 slides) and slide-level (n = 3274 slides, 1249 cases, 37 sites). Interpretability analyses were performed using Testing with Concept Activation Vectors (TCAV), saliency analysis, and pathologist review of clustered patches. RESULTS: The patch-level AUCs are 0.939 (95%CI 0.936–0.941), 0.938 (0.936–0.940), and 0.808 (0.802–0.813) for ER/PR/HER2, respectively. At the slide level, AUCs are 0.86 (95%CI 0.84–0.87), 0.75 (0.73–0.77), and 0.60 (0.56–0.64) for ER/PR/HER2, respectively. Interpretability analyses show known biomarker-histomorphology associations including associations of low-grade and lobular histology with ER/PR positivity, and increased inflammatory infiltrates with triple-negative staining. CONCLUSIONS: This study presents rapid breast cancer biomarker estimation from routine H&E slides and builds on prior advances by prioritizing interpretability of computationally learned features in the context of existing pathological knowledge. Nature Publishing Group UK 2021-07-14 /pmc/articles/PMC9037318/ /pubmed/35602213 http://dx.doi.org/10.1038/s43856-021-00013-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gamble, Paul Jaroensri, Ronnachai Wang, Hongwu Tan, Fraser Moran, Melissa Brown, Trissia Flament-Auvigne, Isabelle Rakha, Emad A. Toss, Michael Dabbs, David J. Regitnig, Peter Olson, Niels Wren, James H. Robinson, Carrie Corrado, Greg S. Peng, Lily H. Liu, Yun Mermel, Craig H. Steiner, David F. Chen, Po-Hsuan Cameron Determining breast cancer biomarker status and associated morphological features using deep learning |
title | Determining breast cancer biomarker status and associated morphological features using deep learning |
title_full | Determining breast cancer biomarker status and associated morphological features using deep learning |
title_fullStr | Determining breast cancer biomarker status and associated morphological features using deep learning |
title_full_unstemmed | Determining breast cancer biomarker status and associated morphological features using deep learning |
title_short | Determining breast cancer biomarker status and associated morphological features using deep learning |
title_sort | determining breast cancer biomarker status and associated morphological features using deep learning |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037318/ https://www.ncbi.nlm.nih.gov/pubmed/35602213 http://dx.doi.org/10.1038/s43856-021-00013-3 |
work_keys_str_mv | AT gamblepaul determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT jaroensrironnachai determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT wanghongwu determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT tanfraser determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT moranmelissa determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT browntrissia determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT flamentauvigneisabelle determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT rakhaemada determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT tossmichael determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT dabbsdavidj determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT regitnigpeter determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT olsonniels determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT wrenjamesh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT robinsoncarrie determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT corradogregs determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT penglilyh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT liuyun determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT mermelcraigh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT steinerdavidf determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning AT chenpohsuancameron determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning |